News & Updates
Filter by Specialty:

Tamibaroterone inhalable dry powder shows broad-spectrum activity against SARS-CoV-2, MERS and H1N1
Researchers from the University of Hong Kong (HKU) have developed a dry powder formulation of tamibaroterone, which displays broad-spectrum antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), and pandemic 2009 influenza A virus (H1N1), when delivered intranasally or through inhalation in mouse and hamster models.
Tamibaroterone inhalable dry powder shows broad-spectrum activity against SARS-CoV-2, MERS and H1N1
12 Oct 2021
MET amplification a predictor of response to crizotinib
A subanalysis of the ongoing phase II PROFILE 1001 study suggests that MET amplification may serve as one of the predictive biomarkers for response to crizotinib among patients with non-small-cell lung cancer (NSCLC).
MET amplification a predictor of response to crizotinib
12 Oct 2021
Real-world data suggest enzalutamide more suitable than abiraterone for post-docetaxel mCRPC
A real-world retrospective study reports significantly longer radiological progression-free survival (rPFS) and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with enzalutamide vs abiraterone acetate after previous docetaxel therapy.
Real-world data suggest enzalutamide more suitable than abiraterone for post-docetaxel mCRPC
12 Oct 2021
Secukinumab: Fewer jabs do the job in psoriasis
New data presented at EADV 2021 support the efficacy of secukinumab 300-mg dose in a 2-mL autoinjector compared with two 150 mg in 1 mL pre-filled syringes or placebo for psoriasis, with no new safety signals observed within 52 weeks.
Secukinumab: Fewer jabs do the job in psoriasis
12 Oct 2021
Early convalescent plasma infusion does not prevent COVID-19 progression
An infusion of convalescent plasma, obtained via blood donation from individuals who have recovered from COVID-19, did not prevent disease progression in high-risk outpatients who presented within 7 days of COVID-19 symptom onset, results of the phase III US-based SIREN-C3PO* study showed.
Early convalescent plasma infusion does not prevent COVID-19 progression
11 Oct 2021
Diet plus exercise keeps BP in check for patients with resistant hypertension
A structured lifestyle modification programme that combines a healthy eating plan and regular aerobic exercise promotes blood pressure (BP) control and improves cardiovascular disease biomarkers in patients with resistant hypertension, as shown in the TRIUMPH study.